[HTML] springer.comFull View

[HTML][HTML] Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing

C Beerts, SY Broeckx, E Depuydt, L Tack… - Arthritis Research & …, 2023 - Springer
Background As current therapies for canine osteoarthritis (OA) provide mainly symptomatic
improvement and fail to address the complex pathology of the disease, mesenchymal stem …
相关文章
[HTML] nih.gov

[HTML][HTML] Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing

C Beerts, SY Broeckx, E Depuydt, L Tack… - Arthritis Research & …, 2023 - ncbi.nlm.nih.gov
Background As current therapies for canine osteoarthritis (OA) provide mainly symptomatic
improvement and fail to address the complex pathology of the disease, mesenchymal stem …

Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing

C Beerts, SY Broeckx, E Depuydt… - Arthritis research …, 2023 - pubmed.ncbi.nlm.nih.gov
Background As current therapies for canine osteoarthritis (OA) provide mainly symptomatic
improvement and fail to address the complex pathology of the disease, mesenchymal stem …
[HTML] biomedcentral.com

[HTML][HTML] Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing

C Beerts, SY Broeckx… - Arthritis …, 2023 - arthritis-research.biomedcentral.com
As current therapies for canine osteoarthritis (OA) provide mainly symptomatic improvement
and fail to address the complex pathology of the disease, mesenchymal stem cells (MSCs) …

Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing

C Beerts, S Broeckx, E Depuydt, L Tack… - Arthritis Research & …, 2023 - biblio.ugent.be
Background As current therapies for canine osteoarthritis (OA) provide mainly symptomatic
improvement and fail to address the complex pathology of the disease, mesenchymal stem …
[PDF] ugent.be

[PDF][PDF] Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing

C Beerts, SY Broeckx, E Depuydt, L Tack, L Van Hecke… - 2023 - backoffice.biblio.ugent.be
Background As current therapies for canine osteoarthritis (OA) provide mainly symptomatic
improvement and fail to address the complex pathology of the disease, mesenchymal stem …

Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing.

C Beerts, SY Broeckx, E Depuydt, L Tack… - Arthritis Research & …, 2023 - europepmc.org
Background As current therapies for canine osteoarthritis (OA) provide mainly symptomatic
improvement and fail to address the complex pathology of the disease, mesenchymal stem …

Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing

C Beerts, SY Broeckx, E Depuydt… - Arthritis Research & …, 2023 - search.proquest.com
Background As current therapies for canine osteoarthritis (OA) provide mainly symptomatic
improvement and fail to address the complex pathology of the disease, mesenchymal stem …

Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing.

C Beerts, SY Broeckx, E Depuydt, L Tack… - Arthritis Research & …, 2023 - europepmc.org
Background As current therapies for canine osteoarthritis (OA) provide mainly symptomatic
improvement and fail to address the complex pathology of the disease, mesenchymal stem …
[PDF] biomedcentral.com

[PDF][PDF] Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing

C Beerts, SY Broeckx, E Depuydt, L Tack… - 2023 - arthritis-research.biomedcentral.com
Background As current therapies for canine osteoarthritis (OA) provide mainly symptomatic
improvement and fail to address the complex pathology of the disease, mesenchymal stem …